BCAL Diagnostics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Shane Ryan

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2.4yrs

Recent management updates

Recent updates

Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?

Aug 08

Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In Growth

Apr 07

Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn Situation

Dec 23

CEO

Shane Ryan

less than a year

Tenure

Mr. Shane Ryan, MBA is Chief Executive Officer of BCAL Diagnostics Limited from 2024. He joined the BCAL Diagnostics Limited on September 21, 2023. He was Chief Operating Officer of BCAL Diagnostics Limite...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jayne Shaw	Co-Founder & Executive Chairman	14.2yrs	AU$180.00k	12.01% A$ 2.9m
Ronald Phillips	Co-Founder & Non-Executive Director	no data	AU$52.31k	10.86% A$ 2.6m
Amani Batarseh	Chief Scientist Officer	no data	AU$377.31k	0.39% A$ 92.5k
John Hurrell	Independent Non-Executive Director & Consultant	less than a year	AU$530.95k	2.18% A$ 523.7k
Shane Ryan	Chief Executive Officer	less than a year	no data	no data
Guy Robertson	CFO & Company Secretary	3.1yrs	no data	no data
Sean Kennedy	Director of Corporate Finance	no data	no data	1.31% A$ 313.5k

0.3yrs

Average Tenure

Experienced Management: BDX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jayne Shaw	Co-Founder & Executive Chairman	14.2yrs	AU$180.00k	12.01% A$ 2.9m
Ronald Phillips	Co-Founder & Non-Executive Director	14.2yrs	AU$52.31k	10.86% A$ 2.6m
John Hurrell	Independent Non-Executive Director & Consultant	less than a year	AU$530.95k	2.18% A$ 523.7k
Mark Burrows	Independent Non-Executive Director	2.8yrs	AU$52.31k	0.55% A$ 133.0k
David Darling	Non-Executive Director	less than a year	no data	no data
Jonathan Alfred Trollip	Independent Non-Executive Director	3.3yrs	AU$52.31k	1.9% A$ 456.3k
Kim Ekroos	Scientific Advisory Board Member	no data	no data	no data
Craig Gedye	Scientific Advisory Board Member	no data	no data	no data
Peter Meikle	Scientific Advisory Board Member	no data	no data	no data
Sanjay Warrier	Scientific Advisory Board Member	2.1yrs	no data	no data
Mary Rickard	Scientific Advisory Board Member	2.1yrs	no data	no data

2.4yrs

Average Tenure

Experienced Board: BDX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

BCAL Diagnostics Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

Co-Founder & Non-Executive Director exercised options to buy AU$212k worth of stock.

BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

High number of new and inexperienced directors

Recent updates

Less than half of directors are independent

First half 2024 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in 1H 2023)

Co-Founder & Non-Executive Director exercised options to buy AU$212k worth of stock.

BCAL Diagnostics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.

BCAL Diagnostics Limited, Annual General Meeting, Nov 22, 2023

Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023

New minor risk - Shareholder dilution

Full year 2023 earnings released: AU$0.024 loss per share (vs AU$0.017 loss in FY 2022)

New minor risk - Financial data availability

Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

New major risk - Market cap size

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.006 loss in 1H 2022)

High number of new and inexperienced directors

BCAL Diagnostics Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In Growth

High number of new and inexperienced directors

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Bcal Diagnostics Limited Provides Additional Information on Recent Analysis to Distinguish Between Blood Samples of Breast Cancer Patients and Normal Control Samples

Bcal Diagnostics Limited Announces Recent Analysis Significantly Improves Commercial Prospects

Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn Situation

Full year 2021 earnings released: AU$0.011 loss per share (vs AU$0.006 loss in FY 2020)

BCAL Diagnostics Limited Commences Collecting Samples for the First Stage of Its Australian Clinical Program

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure